Radiopharm Receives Positive Recommendation to Increase Dose Level in Phase One Dose Escalating Cancer Clinical Trial, Shares Up 5%

MT Newswires Live

04/08

Radiopharm Theranostics (ASX:RAD) received a positive recommendation from the data safety and monitoring committee to progress its clinical-stage radiotherapeutic candidate, lutetium-177-RAD202, to the next dose level of 130 millicurie (mCi) from 75 mCi in the phase one "HEAT" dose escalating clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors, according to a Wednesday Australian bourse filing.

The favorable safety profile allows the firm to accelerate the dose escalation from the second group to the third group, the firm's Chief Executive, Riccardo Canevari, said.

Its shares rose 5% in recent trading on Wednesday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2625990372"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2625990372\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2625990372?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-08 14:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2625990372","market":"sg","top_or_hot":-1,"title":"Radiopharm Receives Positive Recommendation to Increase Dose Level in Phase One Dose Escalating Cancer Clinical Trial, Shares Up 5%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/RDPTF\">Radiopharm Theranostics</a> (ASX:RAD) received a positive recommendation from the data safety and monitoring committee to progress its clinical-stage radiotherapeutic candidate, lutetium-177-RAD202, to the next dose level of 130 millicurie (mCi) from 75 mCi in the phase one \"HEAT\" dose escalating clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors, according to a Wednesday Australian bourse filing.</p><p>The favorable safety profile allows the firm to accelerate the dose escalation from the second group to the third group, the firm's Chief Executive, Riccardo Canevari, said.</p><p>Its shares rose 5% in recent trading on Wednesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Radiopharm Receives Positive Recommendation to Increase Dose Level in Phase One Dose Escalating Cancer Clinical Trial, Shares Up 5%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRadiopharm Receives Positive Recommendation to Increase Dose Level in Phase One Dose Escalating Cancer Clinical Trial, Shares Up 5%\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-04-08 14:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/RDPTF\">Radiopharm Theranostics</a> (ASX:RAD) received a positive recommendation from the data safety and monitoring committee to progress its clinical-stage radiotherapeutic candidate, lutetium-177-RAD202, to the next dose level of 130 millicurie (mCi) from 75 mCi in the phase one \"HEAT\" dose escalating clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors, according to a Wednesday Australian bourse filing.</p><p>The favorable safety profile allows the firm to accelerate the dose escalation from the second group to the third group, the firm's Chief Executive, Riccardo Canevari, said.</p><p>Its shares rose 5% in recent trading on Wednesday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RAD.AU","symbol_name":"RADIOPHARM THERANOSTICS LTD","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2625990372","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2625990372","pubTimestamp":1775629155,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Radiopharm Theranostics  received a positive recommendation from the data safety and monitoring committee to progress its clinical-stage radiotherapeutic candidate, lutetium-177-RAD202, to the next dose level of 130 millicurie  from 75 mCi in the phase one \"HEAT\" dose escalating clinical trial in patients with Human Epidermal Growth Factor Receptor 2 -positive advanced solid tumors, according to a Wednesday Australian bourse filing.The favorable safety profile allows the firm to accelerate the dose escalation from the second group to the third group, the firm's Chief Executive, Riccardo Canevari, said.Its shares rose 5% in recent trading on Wednesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RAD.AU":"RADIOPHARM THERANOSTICS LTD","BK7067":"生物科技"},"translate_title":"Radiopharm在第一阶段剂量递增癌症临床试验中获得增加剂量水平的积极建议，股价上涨5%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RAD.AU":1},"content_text":"Radiopharm Theranostics (ASX:RAD) received a positive recommendation from the data safety and monitoring committee to progress its clinical-stage radiotherapeutic candidate, lutetium-177-RAD202, to the next dose level of 130 millicurie (mCi) from 75 mCi in the phase one \"HEAT\" dose escalating clinical trial in patients with Human Epidermal Growth Factor Receptor 2 (HER2)-positive advanced solid tumors, according to a Wednesday Australian bourse filing.The favorable safety profile allows the firm to accelerate the dose escalation from the second group to the third group, the firm's Chief Executive, Riccardo Canevari, said.Its shares rose 5% in recent trading on Wednesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}